T-B interactions yield CD3+ B cells and CD20+ T cells with pathogenic features in multiple sclerosis. (PubMed, Proc Natl Acad Sci U S A) - Oct 2, 2026 - "Anti-CD20 therapy (ofatumumab) not only depleted masquerading lymphocytes but also prevented their reinduction. Together, we identify CD3+ B cells as footprints of T-B interactions thereby shifting the paradigm of lymphocyte-specific surface markers and implicate masquerading lymphocytes as active contributors to MS immunopathology."
Journal • CNS Disorders • Inflammation • Multiple Sclerosis • CD20
|
|
Arek Kendirli; Atay Vural; Ceren Özdemir; Christoph A Reichel; Eddie A James; Edgar Meinl; Eva Oswald; Fady Shenouda; Jan Kranich; Jan Schmidt; José M Carballido; Julie Boisclair; Magali Jivkov; Nathalie Loll; Philippe Couttet; Rachel Cuttat; Samantha Ho; Selen Ünlü; Selia Baier; Simone Mader; Stephan Winklmeier; Tania Kümpfel; Ulrike Naumann; Valérie Dubost; Walter Georgescu; Yoann Gilbart; Zhongyi Wang
|